Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Told people to buy at 20! We did $$$$$
$23.00
Pipeline looks great and poised to push this higher IMHO
It'l go much much higher imo! $$$
Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $25 to $28.
Great ride after hours yesterday. I’m excited to see their results on the pain asset which should be a huge boost for their share price as well.
Acadia Pharmaceuticals Announces Top-line Results From Pivotal Phase 3 Lavender Trial Of Trofinetide in Rett Syndrome; Trofinetide Met Co-Primary Efficacy Endpoints And Key Secondary Endpoint.
Back to 50 area quick if acad gets some good news! Still holding a few shares from the 5.00 era, mostly freebies but we did add a bit recently. Patience folks, bio's have a way of making millionaires over an over $$$$
Patience folks, acad will perform! $$$$
SAN DIEGO -- (Business Wire)
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 8, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations.
The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-877-4067 for international callers (reference passcode 9213599). A telephone replay of the conference call may be accessed through November 22, 2021 by dialing 855-859-2056 for callers in the United States or Canada and 404-537-3406 for international callers (reference passcode 9213599). The conference call also will be webcast live on Acadia’s website, www.acadia-pharm.com under the investors section and will be archived there until December 6, 2021.
Good for you!!
Even Better News!!!
I passed the first interview to fill Elena Ridloff's CFA position and have been called back in for a second interview!
Hey, if Hunter Biden can be on the board of a U.K. energy company with no experience, the possibilities for me are endless!
I'll right this titanic ship, straight away!
Patience as usual. $$$
Making wealth is fun, huh?
Come on 15.10 ! Let loose those stop losses!
Should I sell Apple stock to buy more Acadia?
WhoooHooo!
Good News!!!
I just applied for the new CFA position, with Acadia, to replace Elena Ridloff.
I'll right this titanic ship, straight away!
We're going to go below $15.10 to trigger stop losses.
Golden parachutes in progress at Acadia pharmaceuticals, starting with Elena Ridloff. It's funny, that with a last name like Rattle-Off, she didn't even rattle off one word during the last conference call. Now, let's hope that Open-Shirt CEO, Steve Davis is the next to be paid 500 million on his departure! Even I could run Acadia much better!
How's the new style of "open-shirt" management doing with Acadia? Oh, I see it's a disaster...
Let's trigger those stop losses at $15.68...
BTW, Steve Davis wore an unbuttoned too low shirt during the Cancord conference call, when he should have worn a suit...
He stuttered often...and the words "Um and Ah" were used most often...
He also clicked the presentation clicker, way too loudly...
He didn't let the women speak...
Optics matter!
What a diarrhea joke!
I’ve been adding to my position on the re-trace.
Excited to see upcoming results and execution on pipeline assets in the near future.
Folks, good evening, hope people are adding to make wealth again here. $$$$$
Down down down in a burning ring of FIRE!!!
Pucker up, buttercup!
Uh oh, when the 1st infrastructure bill is passed today and then the 2nd, human infrastructure bill, it lowers prescription drug prices, thereby taking the profits out of pharma, thereby taking the profits away from pharma investors.
Luckily, Parkison's will be a thing of the past, pending the FDA's decision on that new NDA. No one would even need to Pimavanserin/Nuplazid, so it can be pulled off the market.
Institutional owners are bailing out now, single digits on the way!
FYI, the "infrastructure" bill failed, apparently due to no money to pay for it. I'm not here to debate the legitimacy of the infrastructure bill. My point is, that part of its' pork at the bottom of the bill, was to lower drug prices. If the bill had been approved/passed, the Acadia stock price would have even dropped lower and had lower profits and then during Acadia's next Q3 call, they would have had to lower their sales guidance even moreseo, due to lower profits/not being able to sell Nuplazid at a premium...
I think you meant to say, if the institutional owners start selling off, we're going to be messed over big-time.
Uh oh, if the institutes start selling off their 90% ownership, we're screwed.
RE: "30's coming! Adding here as usual $$$$"
Making wealth is fun, huh?
It's quite a scam to carry out the decimal point to 3 digits...
ACAD definitely possitive news, and should head back UP...???
"The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
5:05 pm ET July 21, 2021 (BusinessWire) Print
--- Pimavanserin met the secondary endpoint of significantly reducing trial discontinuation for any reason by 2.2 fold
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigational treatment in patients with hallucinations and delusions associated with dementia-related psychosis (DRP). The study included patients across five subgroups of dementia: Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia, and vascular dementia.
The HARMONY study was stopped early due to positive efficacy at the pre-planned interim analysis upon recommendation of the trial's independent data safety monitoring board. HARMONY met its primary endpoint by significantly reducing the risk of relapse of psychosis by 2.8 fold compared to placebo in the double-blind period (hazard ratio (HR)=0.35, two-sided p=0.005; one-sided p=0.0023). The study also met its secondary endpoint by significantly reducing the time to trial discontinuation for any reason (HR=0.45, two-sided p=0.005; one-sided p=0.0024). The data from the HARMONY study demonstrates that patients with DRP who had responded to pimavanserin had a significantly lower risk of relapse of psychosis with continuation of pimavanserin compared to placebo up to 26 weeks.
"The relapse prevention design of the HARMONY study mirrors exactly what we do in clinical practice. This landmark trial showed that when patients responded to pimavanserin and then continued treatment, they were almost three times less likely to develop recurrence of their hallucinations and delusions than those patients who discontinued pimavanserin treatment," said the study's lead author, Dr. Pierre N. Tariot, Banner Alzheimer's Institute director. "This is a substantial finding and a significant advance for a critical public health need in our field. There is no FDA approved treatment for DRP, and the majority of antipsychotics currently used off-label have equivocal efficacy and may accelerate cognitive decline."
Pimavanserin was well-tolerated over the nine-month study duration. In a pre-specified analysis, pimavanserin was not associated with a decline in cognition as measured by Mini-Mental State Examination (MMSE) or the onset or worsening of motor symptoms as measured by Extrapyramidal Symptom Rating Scale A (ESRS-A).
"The HARMONY study findings demonstrated three important results. First, in the 12-week open-label period, pimavanserin treatment showed a sustained reduction of psychotic symptoms. Second, in the 26-week double-blind period, patients on pimavanserin had a nearly three-fold reduction of risk of psychosis relapse compared to patients on placebo. Third, pimavanserin was well-tolerated by elderly patients with DRP," said Steve Davis, Chief Executive Officer of Acadia. "We are very pleased that the New England Journal of Medicine has chosen to publish the important results of this study."
About HARMONY
HARMONY was a Phase 3 study designed to evaluate the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis. The study included patients with Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia, and vascular dementia. A total of 392 patients were enrolled in the study, with a mean age of 74.5 years and a mean MMSE score of 16.7. The primary endpoint in the study was time from randomization to relapse of psychosis in the double-blind period as represented by the Kaplan-Meier curve and the hazard ratio.
The HARMONY study included a 12-week, open-label stabilization period during which patients with dementia-related psychosis began treatment with pimavanserin 34 mg once daily. In the open-label period, a majority (61.8%) of eligible subjects (n=351) met the sustained treatment response criteria at Week 8 and Week 12 and entered the double-blind period. Following the open-label period, patients who met pre-specified criteria for sustained treatment response were then randomized into the double-blind period of the study to continue their pimavanserin dose or switched to placebo and followed for up to 26 weeks or until a relapse of psychosis occurred. Pimavanserin met its primary endpoint and was stopped at the pre-planned interim analysis for positive efficacy, demonstrating that pimavanserin significantly reduced the risk of relapse of psychosis by 2.8 fold compared to placebo (HR=0.35, p=0.005).
In the double-blind period, similar, low rates of adverse events were observed, 43 (41.0%) patients on pimavanserin (n=105) and 41 (36.6%) patients on placebo (n=112). Discontinuations in the double-blind period due to adverse events were low, 2.9% for pimavanserin and 3.6% for placebo. Rates of serious adverse events were also low, 4.8% in the pimavanserin group and 3.6% in the placebo group. One death was reported in the open-label period and one death was reported in the pimavanserin group during the double-blind period. Investigators determined that neither death was related to the study drug.
About Dementia-Related Psychosis
Approximately 8 million people in the United States are living with dementia, a condition with a core feature of declining cognition (changes in memory, decision-making abilities, language, etc.) resulting in functional impairment. Dementia is a manifestation of an underlying condition which is often progressive and neurodegenerative in nature.(1) In addition to cognitive decline, dementing illnesses almost universally lead to neuropsychiatric symptoms, which may include hallucinations, delusions, and changes in behavior.
It is estimated that 2.4 million Americans (or 30% of people with dementia) experience dementia-related hallucinations and delusions.(2,3) These symptoms may be frequent and severe and may recur over time. A hallucination is defined as a perception-like experience that occurs without an external stimulus and is sensory (seen, heard, felt, tasted, sensed) in nature. A delusion is defined as a false, fixed belief that is resolutely held despite evidence to the contrary. Dementia-related psychosis occurs in many types of dementia, including Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease dementia, vascular dementia, and frontotemporal dementia. Serious consequences have been associated with psychosis in patients with dementia, such as repeated hospital admissions, increased likelihood of nursing home placement, faster progression of dementia, and increased risk of morbidity and mortality.(4)"
Things looking good here folks! Time to load!
New England Journal of Medicine, a peer reviewed journal you should become familiar with. I’m tired too, and will let the authors and editorial writer speak for themselves.
Who's NEJM? I'm too tired to read the article or Google it's, much nicer to have you explain it thanks.
NEJM provides a partial answer to your questions in an article published in the print version dated 7/22/2021 at pages 309-319, titled “Trial of Pimavanserin in Dementia-Related Psychosis.” We know the Acadia Harmony clinical trial was stopped early for efficacy.
We are not selling our shares of Acadia. I will try to supply a link to that article later tonight, time permitting.
A NEJM editorial appears at pages 372-373, noting that there were 46 million people with various forms of “dementia”, including AD, worldwide. How will FDA regard this data in regard to any label for use negotiations to be conducted in the future is also a question to be answered.
Question for seasoned investors.
I keep hearing bad thing about the economy, inflation, shortages, potential raising of interest rates, leading to a crashed stock market.
My dumb question is, if the market loses 10,20,30, or 40% for example, are all stocks effected?
In case case like the above, is pharma/biotech safer in general, or is nothing safe?
I am down like 39% in ACAD now and have been a long-term holder and have no plans to sell now, but just wondered if I should get rid of my other stocks or move into a safer sector in the market?
What are the general thoughts out there? Market crash yay or nay?
Is pharma/biotech safe in a market crash? Was pharma/biotech safe in the 2008 real estate/stock market crash?
Law firms scavenging en force today.
ACAD appears poised to climb IMHO with pipeline
$27 in pre-market this morning !
On our way !
$25.70
Buckle up and Hold on to your hats !
30's coming! Adding here as usual $$$$
Its going back past 30 folks, been adding here in low 20's, gold mine coming $$$$ patience
I agree this will eventually pay off but it will take some time. I like their pipeline too. The non-opioid pain asset they acquired from CerSci has huge potential as well. This is a long-term play.
I hope you're right. Three weeks is not too long to wait, but one analyst at Mizuho thinks that they will need to do one or two more studies to satisfy the FDA in order to be able to move forward with marketing this indication, and that is too long for me to wait. I think the share price will be over $40 eventually, but I don't think it will be by the end of this year. I believe your patience will eventually be rewarded, but I have other stocks that I think will develop faster with less risk of encountering seemingly capricious and possibly adversarial opposition.
Followers
|
146
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3196
|
Created
|
06/16/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |